Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Hookipa Pharma Stock Surges On HIV Pact With Gilead

Hookipa Pharma Inc (NASDAQ:HOOKamended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ:GILD) for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).

  • In April 2018, Gilead licensed exclusive rights to Hookipa's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). 
  • The companies agreed to collaborate through a joint research phase, after which Gilead had rights for further development. 
  • Under the amended and restated agreement, Hookipa will advance the HIV program through the Phase 1b trial, with funding from Gilead via an upfront payment and equity purchases. 
  • After the Phase 1b trial, Gilead has the exclusive right to assume further development of the program. The HBV portion of the agreement remains unchanged.
  • Hookipa earned a one-time $4 million preclinical milestone payment under the original 2018 agreement. 
  • Upon signing of the amended agreement, Hookipa will receive $15 million. 
  • In addition, Gilead will make a $5 million equity investment in Hookipa and up to an additional $30 million of equity financing that can be drawn at HOOKIPA's discretion by December 31, 2023.
  • Gilead plans to advance the Hepatitis B virus (HBV) program to the IND-enabling stage in 2022.
  • Price Action: HOOK shares are up 41.8% at $1.90 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.